Key terms
About AVTE
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AVTE news
Apr 12
1:11pm ET
Aerovate Therapeutics management to meet virtually with Jefferies
Apr 08
3:18pm ET
Fly Insider: Xilio, Aerovate among weekâs notable insider trades
Apr 01
6:51am ET
Aerovate Therapeutics added ‘Q2 Tactical Ideas List’ at Wells Fargo
Apr 01
5:56am ET
Aerovate Therapeutics: Poised for Market Capitalization Growth on IMPAHCT Trial Success
Apr 01
1:06am ET
Aerovate Therapeutics (NASDAQ:AVTE) On the Verge of Substantial Growth
Mar 27
7:17am ET
Aerovate Therapeutics price target raised to $50 from $27 at BTIG
Mar 26
6:12am ET
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics, Inc. (APGE), SAGE Therapeutics (SAGE)
Mar 25
7:05pm ET
Aerovate Therapeutics: A Strong Buy Ahead of Key Clinical Data Release
Mar 25
4:20pm ET
Aerovate Therapeutics reports FY23 EPS (74c), consensus (71c)
Mar 25
8:00am ET
Aerovate Therapeutics assumed with a Buy at Jefferies
Mar 06
8:09am ET
Aerovate Therapeutics appoints Dable as board of directors
Feb 26
7:36am ET
TD Cowen Sticks to Its Buy Rating for Aerovate Therapeutics (AVTE)
No recent press releases are available for AVTE
AVTE Financials
Key terms
Ad Feedback
AVTE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AVTE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
